What determines quality of life in inclusion body myositis?

R. Sadjadi, Michael R. Rose, Rabi Tawil, Robert Griggs, Charles Thornton, Carlayne Jackson, Anthony Amato, Richard Barohn, David Saperstein, Sharon Nations, John Kissel, Jerry Mendell, Angela Genge, George Karpati, Michael McDermott, Shree Pandya, Deborah Myers, Laura Herbelin, Wendy King, Sheryl HoltLois Finch, John Cowman, Deborah Whalen, Adriana Venturini, Samantha Prisley, Michelle Tagerman, Meredith O'Brien, Lynn Cos, Melinda Wrench, Carla Sherman, Kimberly Harding, Karen Downing, Manuela Triguero, Catherine Morrison, Roza Plesiak, Frieda Barefield, Hannah Briemberg, Robert Holloway, Don Higgins, John Kolassa, Joanne Janciuras, Derick Peterson, William Martens, Stephanie Gregory, Christine Blood

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Background: Quality of life (QoL) assessment allows healthcare professionals to appreciate the patient perspective of their disease. This can help us make a better choice from among the various ways we currently measure the severity of a muscle disease such as inclusion body myositis (IBM). However, we cannot assume that QoL in IBM is just related to disease severity as psychosocial factors may play an important role in determining QoL. Methods: Sixty subjects with IBM had assessments of disease severity and concurrent assessment of mood and QoL using the Short-Form 36 (SF-36). Results: There were significant reductions in Physical functioning, Role physical, General health and Social functioning domains of the SF-36. Functional disability was more indicative of the broader effects of IBM on SF-36 than was the muscle strength sum score. Mood was relatively independent of disease severity and had a different profile of effects on SF-36 domains. Up to 14% of the effect of functional disability on some aspects of QoL was mediated through mood. Conclusions: The functional disability caused by IBM reduces QoL, but psychosocial factors such as mood affect QoL directly and by influencing the degree to which disease severity reduces QoL. Further study should follow the effects of IBM on QoL over time and look at the influence of other psychosocial factors. Such studies may point to psychosocial interventions that may help improve QoL in IBM even if the disease itself cannot be treated.

Original languageEnglish (US)
Pages (from-to)1164-1166
Number of pages3
JournalJournal of Neurology, Neurosurgery and psychiatry
Volume81
Issue number10
DOIs
StatePublished - Oct 1 2010

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'What determines quality of life in inclusion body myositis?'. Together they form a unique fingerprint.

  • Cite this

    Sadjadi, R., Rose, M. R., Tawil, R., Griggs, R., Thornton, C., Jackson, C., Amato, A., Barohn, R., Saperstein, D., Nations, S., Kissel, J., Mendell, J., Genge, A., Karpati, G., McDermott, M., Pandya, S., Myers, D., Herbelin, L., King, W., ... Blood, C. (2010). What determines quality of life in inclusion body myositis? Journal of Neurology, Neurosurgery and psychiatry, 81(10), 1164-1166. https://doi.org/10.1136/jnnp.2009.183863